Home/Pipeline/LTCR‑H3‑1

LTCR‑H3‑1

Advanced primary HBV‑HCC

Pre‑clinicalUpcoming

Key Facts

Indication
Advanced primary HBV‑HCC
Phase
Pre‑clinical
Status
Upcoming
Company

About Lion TCR

Pioneering mRNA‑based TCR‑T cell immunotherapy for HBV‑driven liver cancer in Asia.

View full company profile